A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma.
Saved in:
| Title: | A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma. |
|---|---|
| Authors: | Nakamura, Nobuhiko1 (AUTHOR) nnaka@gifu-u.ac.jp, Kasahara, Senji2 (AUTHOR), Kitagawa, Junichi2 (AUTHOR), Nakamura, Hiroshi1 (AUTHOR), Sawada, Michio3 (AUTHOR), Fukuno, Kenji4 (AUTHOR), Shibata, Yuhei2 (AUTHOR), Kaneda, Yuto4 (AUTHOR), Hara, Takeshi5 (AUTHOR), Kanemura, Nobuhiro1 (AUTHOR), Tsurumi, Hisashi1,5 (AUTHOR), Shimizu, Masahito1 (AUTHOR) |
| Source: | Experimental Hematology & Oncology. 2/25/2022, Vol. 11 Issue 1, p1-4. 4p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 21623619 |
|---|---|
| DOI: | 10.1186/s40164-022-00264-3 |
